Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25787993
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 BMB+Rep
2015 ; 48
(5
): 266-70
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Isocitrate dehydrogenase mutations: new opportunities for translational research
#MMPMID25787993
Keum YS
; Choi BY
BMB Rep
2015[May]; 48
(5
): 266-70
PMID25787993
show ga
Over the last decade, comprehensive genome-wide sequencing studies have enabled
us to find out unexpected genetic alterations of metabolism in cancer. An example
is the identification of arginine missense mutations of isocitrate
dehydrogenases-1 and -2 (IDH1/2) in glioma, acute myeloid leukemia (AML),
chondrosarcomas, and cholangiocarcinoma. These alterations are closely associated
with the production of a new stereospecific metabolite, (R)-2-hydroxyglutarate
(R-2HG). A large number of follow-up studies have been performed to address the
molecular mechanisms of IDH1/2 mutations underlying how these events contribute
to malignant transformation. In the meanwhile, the development of selective
mutant IDH1/2 chemical inhibitors is being actively pursued in the scientific
community and pharmaceutical industry. The present review article briefly
discusses the important findings that highlight the molecular mechanisms of
IDH1/2 mutations in cancer and provides a current status for development of
selective mutant IDH1/2 chemical inhibitors.